Technical Data
AKAP9 (A Kinase (PRKA) Anchor Protein 9, PRKA9, CG-NAP, Yotiao, AKAP350, AKAP450, HYPERION, KIAA0803, AKAP120-like Protein, Kinase N-associated Protein, A-kinase Anchoring Protein 450, A-kinase Anchor Protein 350kD, Protein Kinase A Anchoring Protein 9, C
The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins which have the common function of binding to the regulatory subunit of protein kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family. Alternate splicing of this gene results in many isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon and phosphodiesterase 4D3.

Suitable for use in Peptide ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Peptide ELISA: 1:32,000
Western Blot: 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanGoat
Synthetic peptide corresponding to AKAP9.
Purified by immunoaffinity chromatography.
Supplied as a liquid in Tris-saline, pH 7.3, 0.5% BSA, 0.02% sodium azide.
Recognizes human AKAP9 at ~450kD in lysates of cell line HepG2 (calculated MW of 454kD according to NP_ 671700.1). This antibody is expected to recognize isoforms 1, 2 and 3 (NP_671700.1; NP_005742.4; NP_671714.1 respectively). The isoforms Yotiao, AKAP350B and AKAP350C are not recognized. Species Crossreactivity: mouse
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005 Jan;115(1):94-101.